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Two main molecular targets of 
∆9- tetrahydrocannabinol (∆9-THC), the 
psychoactive principle of Cannabis sativa, 
are type-1 (CB
1
) and type-2 (CB
2
) cannabi-
noid receptors (Howlett et al., 2010). In the 
past few years many endogenous agonists of 
CB receptors have been characterized, and 
are collectively called “endocannabinoids” 
(Maccarrone et al., 2010). They are mainly 
amides and esters of long-chain polyunsat-
urated fatty acids isolated from brain and 
peripheral tissues and, although structurally 
different from plant cannabinoids, share 
critical pharmacophores with ∆9-THC 
(Pertwee, 2010). Two arachidonate deriva-
tives, N-arachidonoylethanolamine (anan-
damide, AEA) and 2-arachidonoylglycerol 
(2-AG), were shown to mimic ∆9-THC by 
functionally activating CB receptors, and 
these are the endocannabinoids whose 
biological activity has been best character-
ized to date (Di Marzo, 2009; Maccarrone 
et al., 2010).
CB
1
 receptor is the most abundant G 
protein-coupled receptor (GPCR) in the 
brain (Howlett et al., 2010). Together with 
its endogenous agonists (AEA, 2-AG, and 
other congeners), CB
1
 belongs to an ancient 
neurosignaling system that plays important 
control functions within the central nerv-
ous system (Katona and Freund, 2008). 
Alterations in this so-called “endocan-
nabinoid system” have been extensively 
investigated in a wide range of neurode-
generative and neuroinflammatory disor-
ders, spanning from Alzheimer’s disease, 
Parkinson’s disease and Huntington’s dis-
ease, to amyotrophic lateral sclerosis and 
multiple sclerosis (Bisogno and Di Marzo, 
2010). For this reason, research on the 
therapeutic potential of drugs modulat-
ing the endocannabinoid system is very 
intense (Di Marzo, 2009). More recently, 
it has become evident the involvement of 
membrane lipids, especially cholesterol 
and glycosphingolipids, in regulating the 
function of GPCRs like β
2
-adrenergic and 
serotonin
1A
 receptors, as well as of several 
other membrane-associated proteins like 
caveolins (Pontier et al., 2008; Prinetti et al., 
2009; Paila et al., 2010; Shrivastava et al., 
2010). Also a role for membrane choles-
terol in the functional regulation of CB
1
 
has been well-documented (for an updated 
review see Dainese et al., 2010). Acute cho-
lesterol depletion by methyl-β-cyclodextrin 
has been shown to double CB
1
-dependent 
signaling via adenylyl cyclase and mitogen-
activated protein kinases in neuronal 
cells (Bari et al., 2005a,b). Conversely, it 
has been reported that in the same cells 
CB
1
-dependent binding and signaling 
was significantly reduced by cholesterol 
enrichment (Bari et al., 2005a,b, 2006). 
Notably, the CB
2
 receptor that is struc-
turally and functionally related to CB
1
 is 
completely insensitive to the modulation of 
membrane cholesterol content (Bari et al., 
2006), and does not reside in cholesterol-
rich microdomains like lipid rafts (Bari 
et al., 2006; Rimmerman et al., 2008). As 
yet, the molecular basis for the different 
response of these two receptor subtypes 
to cholesterol remains unclear, although 
its impact on the therapeutic exploitation 
of CB
1
-dependent endocannabinoid sign-
aling versus that dependent on CB
2
 could 
be immense.
Here, I would like to comment that sub-
tle, yet specific, differences might underpin 
the differential sensitivity of CB
1
 and CB
2
 
to membrane cholesterol, possibly explain-
ing the apparent redundancy of having 
two largely overlapping receptor subtypes 
that are activated by similar compounds 
(endocannabinoids) and trigger similar 
transduction pathways: (i) inhibition of 
adenylyl cyclase, (ii) regulation of ionic 
currents (e.g., inhibition of voltage-gated 
L, N, and P/Q-type Ca2+ channels, and acti-
vation of K+ channels), and (iii) activation 
of focal adhesion kinase, mitogen-activated 
protein kinase, and cytosolic phospholi-
pase A
2
 (Di Marzo, 2009; Maccarrone et al., 
2010).
In general, cholesterol may act on the 
conformation of a membrane recep-
tor by indirectly altering the physico-
chemical properties of the bilayer, or by 
directly  interacting with the receptor itself. 
Although a unique conserved structural 
determinant for protein interaction with 
cholesterol has not yet been identified, a 
well-known motif is the cholesterol inter-
action/recognition amino acid sequence 
consensus [L/V-X
(1–5)
-Y-X
(1–5)
-R/K], named 
CRAC (Epand, 2006). This motif has been 
demonstrated in caveolin-1, peripheral-
type benzodiazepine receptor (Li and 
Papadopoulos, 1998; Jamin et al., 2005), 
and in other proteins targeted to lipid rafts 
(Xie et al., 2010). Interestingly, by sequence 
alignment of human CB
1
 and CB
2
 we have 
recently identified the presence of CRAC in 
the last 11 amino acids of the transmem-
brane helix 7 of both CB
1
 and CB
2
 (Oddi 
et al., 2011). In particular, we found that in 
the highly conserved CRAC region (82% 
amino acid identity), CB
1
 differs from CB
2
 
for one residue only: lysine 402 of CB
1
 
(Figure 1) corresponds to glycine 304 in 
CB
2
 (Oddi et al., 2011). We also found that 
the CB
1
(K402G) mutant where the CRAC 
sequence of CB
1
 was converted into that 
of CB
2
 had a reduced propensity to reside 
in cholesterol-rich membrane regions, and 
lost its sensitivity to membrane cholesterol 
enrichment (Oddi et al., 2011). Therefore, 
one residue in complex proteins like GPCRs 
can be enough to direct their interaction 
with membrane lipids, thus affecting signal 
transduction thereof.
Different non-mutually exclusive mech-
anisms could be proposed to explain the 
differential sensitivity of CB
1
 and CB
2
 to 
membrane cholesterol: (i) compartmentali-
zation in cholesterol-rich microdomains; 
(ii) caveolar endocytosis; (iii) cholesterol-
dependent receptor dimerization; (iv) 
hydrophobic mismatch; (v) modulation 
of the rate of endocannabinoid movement 
within the membrane (Dainese et al., 2010). 
Additionally, it is possible that the differ-
ent effect of membrane cholesterol on CB
1
 
and CB
2
 is due to subtle differences in the 
domain(s) that interact(s) with the sur-
rounding (non-annular) lipids, by  analogy 
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lipids. As a consequence, the membrane 
environment might play a role in receptor-
dependent signaling, with a potential impact 
on several neurotransmission pathways, as 
well as several neurodegenerative/neuroin-
flammatory diseases where CB
1
 is known 
to play a role. More in general, it should 
be recalled that CB
1
-dependent signaling 
impacts fundamental processes as differ-
ent as immune response, energy homeos-
tasis, reproduction, and skin differentiation 
(Di Marzo, 2009; Maccarrone et al., 2010), 
thus it can be anticipated that cholesterol-
dependent regulation of CB
1
 can have a 
physiological relevance well-beyond the 
central nervous system.
In conclusion, membrane environment 
seems to be critical for the regulation of sig-
nal transduction pathways triggered by G 
with other GPCRs (Paila et al., 2010). 
Additionally, other lipid-interacting resi-
dues might direct the interaction of CB
1
 
with the surrounding membrane lipids, e.g., 
cysteine 415 in its C-terminal (Figure 1), 
that could be the target of palmitoylation 
(Dainese et al., 2010). The latter revers-
ible post-translational modification can be 
used by cells to regulate CB
1
 targeting to 
cholesterol-rich subdomains of the mem-
brane, thus influencing its interaction with 
coupled G proteins.
I believe that the comparison between 
CB
1
 and CB
2
 might represent an interesting 
paradigm that goes well-beyond endocan-
nabinoid signaling. In fact, the modulation 
of CB
1
 by cholesterol might disclose a novel 
ligand–receptor interaction, where a third 
player comes into the game: membrane 
Figure 1 | Three-dimensional model of CB1, based on sequence alignment with visual rhodopsin in 
the inactivated state (PDB code: 1F88). The model was obtained using the protein structure homology-
modeling server SWISS-MODEL, integrated in the Deep-View program (Dainese et al., 2010). The three 
residues (V392, Y397, K402) that form the CRAC sequence are represented as yellow spheres, sized to the 
Van der Waals radii; these residues belong to the transmembrane helix 7 of CB1. Recently, we have 
generated a mutant where a lysine residue (K402) was substituted by glycine, thus converting the CRAC 
sequence of CB1 into that of CB2 (Oddi et al., 2011). Additionally, the C-terminal component of CB1, i.e., the 
intracellular juxtamembrane α-helix 8, contains a cysteine residue (C415, in green) that could be 
constitutively palmitoylated. See text for details. The model was kindly provided by Dr. Enrico Dainese 
(University of Teramo, Italy).
protein-coupled receptors like CB
1
. Despite 
the three-dimensional complexity of these 
proteins, we learn from the comparison of 
CB
1
 with CB
2
 that just one amino acid resi-
due can direct receptor functioning, calling 
for attention on the plasma membrane as 
a key-player in ligand recognition on the 
cell surface.
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